A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate

Inclusion Criteria:

- Healthy as determined by a responsible and experienced physician, based on a medical
evaluation including medical history, physical examination, laboratory tests and
cardiac monitoring. A subject with a clinical abnormality or laboratory
parameter(s), which is/are not specifically listed in the inclusion or exclusion
criteria, outside the reference range for the population being studied may be
included only if the Investigator and GlaxoSmithKline (GSK) Medical Monitor agree and
document that the finding is unlikely to introduce additional risk factors and will
not interfere with the study procedures. Subjects whose laboratory values are outside
the normal ranges will be excluded from enrolment.

- Male or female aged between 18 and 65 years of age inclusive, at the time of signing
the informed consent.

- Alanine Aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5x Upper Limit
of Normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is
fractionated and direct bilirubin <35%).

- QTcF <440 milliseconds (msec) based on averaged corrected QT interval (QTc) values of
triplicate electrocardiogram (ECGs) obtained over a brief recording period at
screening and no history of additional risk factors for Torsades des Pointes (e.g.,
heart failure or family history of Long QT Syndrome).

- A female subject is eligible to participate if she is of: Non-childbearing potential
defined as pre-menopausal females with a documented tubal ligation or hysterectomy
[for this definition, "documented" refers to the outcome of the
investigator's/designee's review of the subject's medical history for study
eligibility, as obtained via a verbal interview with the subject or from the
subject's medical records]; or postmenopausal defined as 12 months of spontaneous
amenorrhea [in questionable cases a blood sample with simultaneous follicle
stimulating hormone (FSH) > 40 milli-international units per (MIU)/ millilitre (mL)
and estradiol <40 picograms (pg)/mL (<147 picomoles (pmol)/liter [L]) is
confirmatory]. [Females on hormone replacement therapy (HRT) and whose menopausal
status is in doubt will be required to use one of the contraception methods, if they
wish to continue their HRT during the study. Otherwise, they must discontinue HRT to
allow confirmation of post-menopausal status prior to study enrolment. For most forms
of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood
draw; this interval depends on the type and dosage of HRT. Following confirmation of
their post-menopausal status, they can resume use of HRT during the study without use
of a contraceptive method.]; Child-bearing potential with negative pregnancy test as
determined by serum or urine human chorionic gonadotropin (hCG) test at screening or
prior to dosing AND Agrees to use one of the contraception methods for an appropriate
period of time (as determined by the product label or investigator) prior to the
start of dosing to sufficiently minimize the risk of pregnancy at that point. Female
subjects must agree to use contraception until 56-days post first dose. OR has only
same-sex partners, when this is her preferred and usual lifestyle.

- Body Mass Index (BMI) within the range 18.5 to 31.0 kilogram/square meter (kg/m^2)
(inclusive) and body weight between >=36kilogram (kg) and <=100kg.

- Capable of giving written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form.

Exclusion Criteria:

- The subject's average triplicate (at screening after approximately 5 minutes at rest
in the semi-supine position) systolic blood pressure is outside the range of 80-140
millimeters of mercury (mmHg), or diastolic blood pressure is outside the range of
45-90mmHg or heart rate is outside the range of 40-100 beats per minute (bpm).

- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within a 56-day period.

- Lactating females.

Criteria Based Upon Medical Histories:

- Current or chronic history of liver disease, or known hepatic or biliary
abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

- History of regular alcohol consumption within 6 months of the study defined as: an
average weekly intake of >21 units for males or >14 units for females. One unit is
equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1
glass (125 mL) of wine or 1 (25 mL) measure of spirits.

- History of sensitivity to heparin or heparin-induced thrombocytopenia.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or GSK
Medical Monitor, contraindicates their participation.

- History of thalassaemia; or current or past history of methemoglobinemia or
methemoglobin percentage above the reference range at screening.

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.

- Consumption of Seville oranges, grapefruit or grapefruit juice and/or pummelos,
exotic citrus fruits, or grapefruit hybrids from 7 days prior to the first dose of
study medication.

- Use of prescription (except female contraception) or non-prescription drugs,
including vitamins, herbal and dietary supplements (including St John's Wort) within
7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives
(whichever is longer) prior to the first dose of study medication, unless in the
opinion of the Investigator and GSK Medical Monitor the medication will not interfere
with the study procedures or compromise subject safety.

Criteria Based Upon Diagnostic Assessments:

- Subjects with a haemoglobin values outside the lower limit of normal range. A single
repeat is allowed for eligibility determination.

- Documented phenotypic Glucose-6-phosphate dehydrogenase (G6PD) deficiency, determined
by a quantitative assay of enzyme activity. Defined as <70% of locally defined
median.

- Potassium <4.0 millimoles (mmol)/L and Magnesium <1.8 mg/ deciliter (dL). Subjects
with potassium (K) and magnesium (Mg) values below these screening or on Day-1 may be
treated with oral supplementation and be retested for eligibility prior to dosing.

- Cotinine levels indicative of smoking or history or regular use of tobacco- or
nicotine-containing products within 30 days prior to screening.

- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
result within 3 months of screening

- A positive pre-study drug/alcohol screen.

- A positive test for human immunodeficiency virus (HIV) antibody.